You will be shown inclusion or exclusion criteria for a clinical trial. Given these criteria, your task is to extract all unique entities of the following types: ["Observation", "Condition", "Procedure", "Drug", "Temporal", "Multiplier", "Qualifier", "Negation", "ReferencePoint", "Scope", "Value", "Mood", "Device", "Visit", "Measurement", "Person"].

Please return the output as a JSON object of the format: {"Condition" : ["breast cancer", ...], "Device" : ["ports", ...], "Drug" : ["Atenolol", ...], "Measurement" : ["blood pressure", ...], "Mood" : ["suspected", ...], "Multiplier" : ["more than two", ...], "Negation" : ["no", ...], "Observation" : ["history", ...], "Person" : ["male", ...], "Procedure" : ["surgery", ...], "Qualifier" : ["severe", ...], "ReferencePoint" : ["enrollment", ...], "Scope" : ["infection", ...], "Temporal" : ["one day", ...], "Value" : ["50%", ...], "Visit" : ["ICU", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

a licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. NOTE: The term "licensed" refers to a United States Food and Drug Administration (FDA)-approved kit, which is required for all IND studies, or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally. Non-US sites are encouraged to use US FDA-approved methods for IND studies. WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (eg, indirect versus competitive), or a Western blot or a plasma HIV-1 RNA. OR
Documentation of HIV diagnosis in the medical record by a healthcare provider.
Tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF)/TAF-containing fixed-dose combination regimens
Ritonavir (RTV) to cobicistat (COBI)/COBI-containing fixed-dose combination regimens
TDF to TAF/TAF-containing fixed-dose combination regimens
RTV to COBI/COBI-containing fixed-dose combination regimens
HIV-1 plasma RNA less than 50 copies/mL obtained within 90 days prior to study entry by any FDA-approved assay at any United States laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs.
No more than one HIV-1 plasma RNA greater than or equal to 50 and less than 200 copies/mL (only one "blip") in the past 6 months with a subsequent HIV-1 plasma RNA less than 50 copies/mL. NOTE: There should be no plasma HIV-1 RNA greater than 200 copies/mL within the 6 months prior to study entry.
HAND diagnosis (ANI, MND, or HAD) within 60 days prior to study entry. HAND is defined as at least mild impairment on neurocognitive testing (more than one standard deviation below appropriate normative data in two domains of functioning) and no severely confounding factors.
Absolute neutrophil count (ANC) greater than or equal to 500/mm^3
Hemoglobin greater than or equal to 7.5 g/dL
Platelet count greater than or equal to 40,000/mm^3
Creatinine less than or equal to 2.0 x upper limit of normal (ULN)
Aspartate transaminase (AST) less than or equal to 5 x ULN
Alanine transaminase (ALT) less than 3 x ULN
Alkaline phosphatase less than or equal to 5 x ULN
Total bilirubin less than 1.5 x ULN. NOTE: If the potential participant is taking an indinavir (IDV)- or atazanavir (ATV)-containing regimen at the time of screening, total bilirubin less than or equal to 5 x ULN is acceptable.
Creatinine clearance (CrCl) greater than or equal to 60 mL/min, either measured or estimated by Cockcroft-Gault equation. NOTE: A calculator for estimating the CrCl can be found at www.fstrf.org/ACTG/ccc.html
Females of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, ie, who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, hysterectomy or bilateral salpingectomy or bilateral oophorectomy or tubal ligation) must have a negative serum or urine pregnancy test by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care (POC) / CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate external quality assurance programs within 48 hours prior to study entry
Females of reproductive potential must agree not to participate in the conception process (ie, active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, must use at least one reliable form of contraception. Female participants must use contraceptives while receiving study treatment and for 6 weeks after stopping study treatment. More information on this criterion is available in the protocol.
Men and women 18 years of age and older who are able to complete the neuropsychological tests
Ability and willingness of participant or a legally authorized representative (see protocol for more information) to provide informed consent
Ability and willingness to take oral study medications
{"Condition": ["MND", "ANI", "severely confounding factors", "HIV diagnosis", "HAD", "HAND"], "Device": [], "Drug": ["atazanavir (ATV)", "Tenofovir disoproxil fumarate (TDF)", "tenofovir alafenamide fumarate (TAF)", "indinavir (IDV)", "Ritonavir (RTV)", "RTV", "TAF", "COBI", "cobicistat (COBI)", "TDF"], "Measurement": ["Hemoglobin", "Aspartate transaminase (AST)", "Total bilirubin", "Creatinine", "Creatinine clearance (CrCl)", "total bilirubin", "HIV-1 plasma RNA", "Absolute neutrophil count (ANC)", "plasma HIV-1 RNA", "Alanine transaminase (ALT)", "Alkaline phosphatase", "neurocognitive testing", "Platelet count"], "Mood": [], "Multiplier": ["in two domains of functioning", "No more than one"], "Negation": ["no"], "Observation": ["able to complete"], "Person": ["women", "Men", "age"], "Procedure": ["regimen", "TAF-containing fixed-dose combination regimens", "Cockcroft-Gault equation", "neuropsychological tests", "COBI-containing fixed-dose combination regimens"], "Qualifier": ["at least mild"], "ReferencePoint": ["study entry"], "Scope": ["ANI, MND, or HAD", "indinavir (IDV)- or atazanavir (ATV)", "Total bilirubin less than 1.5 x ULN", "at least mild impairment on neurocognitive testing (more than one standard deviation below appropriate normative data in two domains of functioning) and no severely confounding factors", "indinavir (IDV)- or atazanavir (ATV)-containing regimen at the time of screening, total bilirubin less than or equal to 5 x ULN"], "Temporal": ["in the past 6 months", "within the 6 months prior to study entry", "within 60 days prior to study entry", "at the time of screening", "within 90 days prior to study entry", "subsequent"], "Value": ["greater than or equal to 7.5 g/dL", "less than 3 x ULN", "greater than or equal to 60 mL/min", "more than one standard deviation below appropriate normative data", "less than 50 copies/mL", "less than or equal to 2.0 x upper limit of normal (ULN)", "less than or equal to 5 x ULN", "less than 1.5 x ULN", "older wh le to com", "impairment", "greater than or equal to 500/mm^3", "greater than 200 copies/mL", "greater than or equal to 50 and less than 200 copies/mL", "greater than or equal to 40,000/mm^3"], "Visit": []}